ASX:ICS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ICS Global Limited, an investment holding company, provides medical billing services in Australia and the United Kingdom.


Snowflake Analysis

Flawless balance sheet with outstanding track record.

Share Price & News

How has ICS Global's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ICS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.5%

ICS

0.02%

AU Healthcare

2.2%

AU Market


1 Year Return

94.1%

ICS

-3.4%

AU Healthcare

-10.5%

AU Market

Return vs Industry: ICS exceeded the Australian Healthcare industry which returned -1.5% over the past year.

Return vs Market: ICS exceeded the Australian Market which returned -10.3% over the past year.


Shareholder returns

ICSIndustryMarket
7 Day0.5%0.02%2.2%
30 Day0.5%2.6%0.1%
90 Day18.1%24.0%17.5%
1 Year105.8%94.1%-0.5%-3.4%-6.9%-10.5%
3 Year134.1%96.0%7.4%-2.4%16.1%0.8%
5 Year105.9%63.3%10.7%-5.3%31.2%2.9%

Price Volatility Vs. Market

How volatile is ICS Global's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ICS Global undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ICS (A$1.96) is trading below our estimate of fair value (A$46.18)

Significantly Below Fair Value: ICS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ICS is poor value based on its PE Ratio (14.5x) compared to the Healthcare industry average (13.5x).

PE vs Market: ICS is good value based on its PE Ratio (14.5x) compared to the Australian market (16x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ICS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ICS is overvalued based on its PB Ratio (3.2x) compared to the AU Healthcare industry average (1.4x).


Next Steps

Future Growth

How is ICS Global forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ICS Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has ICS Global performed over the past 5 years?

4.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ICS has high quality earnings.

Growing Profit Margin: ICS's current net profit margins (22.5%) are higher than last year (16%).


Past Earnings Growth Analysis

Earnings Trend: ICS's earnings have grown by 4.7% per year over the past 5 years.

Accelerating Growth: ICS's earnings growth over the past year (66.6%) exceeds its 5-year average (4.7% per year).

Earnings vs Industry: ICS earnings growth over the past year (66.6%) exceeded the Healthcare industry 4.3%.


Return on Equity

High ROE: ICS's Return on Equity (22.1%) is considered high.


Next Steps

Financial Health

How is ICS Global's financial position?


Financial Position Analysis

Short Term Liabilities: ICS's short term assets (A$5.8M) exceed its short term liabilities (A$3.4M).

Long Term Liabilities: ICS's short term assets (A$5.8M) exceed its long term liabilities (A$454.7K).


Debt to Equity History and Analysis

Debt Level: ICS is debt free.

Reducing Debt: ICS had no debt 5 years ago.

Debt Coverage: ICS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ICS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is ICS Global current dividend yield, its reliability and sustainability?

3.57%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ICS's dividend (3.57%) is higher than the bottom 25% of dividend payers in the Australian market (2.51%).

High Dividend: ICS's dividend (3.57%) is low compared to the top 25% of dividend payers in the Australian market (6.39%).


Stability and Growth of Payments

Stable Dividend: ICS has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: ICS's dividend payments have increased, but the company has only paid a dividend for 8 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (66.7%), ICS's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.0yrs

Average board tenure


CEO

ICS Global has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Garry Chapman
Executive Chairman & MD of Medical Billing Service4.83yrsAU$246.51k1.65% A$341.3k
Gregory Quirk
Company Secretary & Independent Non-Executive Director10.25yrsAU$56.07k2.91% A$602.6k
Kevin Barry
Independent Non-Executive Chairman10yrsAU$74.07k5.05% A$1.0m
Victor Shkolnik
Independent Non-Executive Director10yrsAU$38.07k2.96% A$612.1k
James Canning-Ure
Independent Non-Executive Director9.92yrsAU$56.07k0.47% A$97.5k

10.0yrs

Average Tenure

Experienced Board: ICS's board of directors are seasoned and experienced ( 10 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ICS Global Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ICS Global Limited
  • Ticker: ICS
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$20.678m
  • Shares outstanding: 10.60m
  • Website: https://icsglobal.com.au

Location

  • ICS Global Limited
  • 20 Bond Street
  • Suite 3.03
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ICSASX (Australian Securities Exchange)YesOrdinary SharesAUAUDDec 1999
ICSCHIA (Chi-X Australia)YesOrdinary SharesAUAUDDec 1999

Biography

ICS Global Limited, an investment holding company, provides medical billing services in Australia and the United Kingdom. The company offers medical billing and collection services to medical consultants and specialists. ICS Global Limited was founded in 1999 and is based in Sydney, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/07 10:36
End of Day Share Price2020/07/07 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.